Clinical and laboratory predictors of monogenic very early onset inflammatory bowel disease

Clin Immunol. 2022 Jul:240:109047. doi: 10.1016/j.clim.2022.109047. Epub 2022 May 22.

Abstract

Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract. Treatment for patients who have a monogenic cause of their IBD, often the youngest children, known as very early onset IBD (VEO-IBD), can be different from standard treatment for polygenic cases. Yet, ascertainment of these patients is difficult.

Methods: We analyzed cases of VEO-IBD to understand the breadth of monogenic etiology and to identify clinical, laboratory, and flow cytometric correlates of this subpopulation.

Results: Genetic causes of very early onset inflammatory bowel disease are highly diverse ranging from pure epithelial defects to classic T cell defects. Flow cytometry, other than testing for chronic granulomatous disease, has a low sensitivity for monogenic etiologies. Poor growth was a clinical feature associated with monogenic causality.

Conclusions: Genetic testing is, at this moment, the most robust method for the identification of monogenic cases of very early onset IBD.

Keywords: Flow cytometry; Inborn error of immunity; Inflammatory bowel disease; Monogenic; Primary immunodeficiency.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Age of Onset
  • Child
  • Genetic Testing
  • Humans
  • Inflammatory Bowel Diseases* / diagnosis
  • Inflammatory Bowel Diseases* / genetics
  • Intestines